Skip to content
10-K

Annual Report

Hepion Pharmaceuticals, Inc. CTRVP HEPA

0001641172-25-003250

← back to feed
Filed
Apr 8, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Apr 8, 2025 10.98M sh
Shares Diluted restated FY 2024 · Dec 31, 2023 79.42K sh
Capex FY 2024 · Dec 31, 2023 $14.3K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$40.89M
Current Liabilities FY 2024 · Dec 31, 2023 $5.29M
Total Liabilities FY 2024 · Dec 31, 2023 $10.81M
Current Assets FY 2024 · Dec 31, 2023 $17.49M
Total Assets FY 2024 · Dec 31, 2023 $18.09M
Eps Diluted restated FY 2024 · Dec 31, 2023 −$616.07
Eps Basic restated FY 2024 · Dec 31, 2023 −$616.07
Sga Expense FY 2024 · Dec 31, 2023 $9.62M
Rd Expense FY 2024 · Dec 31, 2023 $35.64M
Net Income FY 2024 · Dec 31, 2023 −$48.93M
Operating Income FY 2024 · Dec 31, 2023 −$48.45M
Stockholders Equity FY 2024 · Dec 31, 2022 $49.86M